Antibe: Canaccord Lowers Price Target After Co-Leading $40.4 Million Financing
Wednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought deal was for 6.7 million
Read moreWednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought deal was for 6.7 million
Read moreMoney continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest
Read moreEarlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm in China. The deal includes
Read moreRecently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company developing a nonsteroidal anti-inflammatory drugs
Read moreIt appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it had previously received shareholder approval
Read moreAntibe Therapeutics (TSXV: ATE) this past week published results on its latest drug development for the treatment of osteoarthritis pain.
Read more